Merck lines up a buyout deal for soon-to-be women's health spinout
A year after revealing plans to spin off its women’s health portfolio, Merck is lining up a buyout deal to get the new company started.
Organon has struck an up to $240 million deal to acquire Alydia Health, a medical device company working on technology to control and treat abnormal postpartum uterine bleeding or hemorrhage. Alydia will pull in $215 million upfront, including $50 million before the company is officially spun out. And it stands to pocket up to $25 million in milestones.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.